Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2010493 | 0.82 | ALDH1A1 (0.42) | KMT2AMEN1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL2010479 | 0.79 | ALDH1A1 (0.48) | KMT2AMEN1MAPTALDH1A1LMNA | |
| SCHEMBL11269628 | 0.77 | KMT2A (0.55) | HSD17B10KMT2AMEN1MAPTPLA2G1B | |
| SCHEMBL2084055 | 0.76 | HSD17B10 (0.60) | HSD17B10KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL4297302 | 0.74 | LOXL2 (0.53) | ALDH1A1POLB | |
| SCHEMBL868877 | 0.74 | HSD17B10 (0.62) | HSD17B10KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL2205749 | 0.74 | HSD17B10 (0.62) | HSD17B10KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL7786691 | 0.74 | HSD17B10 (0.62) | HSD17B10KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL4533106 | 0.73 | NPBWR1 (0.51) | HSD17B10KMT2AMEN1MAPTPLA2G1B | |
| SCHEMBL6819384 | 0.73 | PTPRF (0.59) | HSD17B10KMT2AMEN1MAPTPLA2G1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120322768-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING PROTOZOAN INFECTIONS | QUEEN MARY & WESTFIELD COLLEGE (GB) | 2012-12-20 | — | — | US | disclosed |
| WO-2011066416-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF PROTOZOAN INFECTIONS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2011-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322768-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING PROTOZOAN INFECTIONS | PHOSPHO1, CYCS, DPM1 | HSD17B10 1468/4885KMT2A 2482/4885MEN1 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.